Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study

Study limitation reported by the research below: “TACE procedures were not standardised (technique and frequency per investigator discretion), which may limit generalisability and introduces heterogeneity across sites.”